Change history
17 February 2022
The image was tagged in XML incorrect as MediaInlineImage.
References
Koh A, Lai TYY, Takahashi K, Wong TY, Chen L-J, Ruamviboonsuk P, et al. Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial. JAMA Ophthalmol. 2017;135:1206–13.
Lim TH, Lai TYY, Takahashi K, Wong TY, Chen L-J, Ruamviboonsuk P, et al. Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: The EVEREST II Randomized Clinical Trial. JAMA Ophthalmol. 2020;138:935–42.
Author information
Authors and Affiliations
Contributions
CHV, LPW, KYCT, and CMGC developed the infographic design. CHV prepared the infographic. CMGC, SSS, KYCT, LPW, CZS, and RG edited and reviewed the infographic and provided the scientific expert advice.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Vyas, C.H., Lott, P.W., Gunatheesan, R. et al. Infographic: Everest II study “Which is superior? Combination therapy or monotherapy for polypoidal choroidal vasculopathy (PCV) treatment”. Eye 36, 1140–1141 (2022). https://doi.org/10.1038/s41433-021-01873-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41433-021-01873-8
